Supernus Pharmaceuticals, Inc. $SUPN Shares Acquired by SG Americas Securities LLC

SG Americas Securities LLC lifted its stake in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 2,847.0% during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 377,213 shares of the specialty pharmaceutical company’s stock after buying an additional 364,413 shares during the quarter. SG Americas Securities LLC owned approximately 0.66% of Supernus Pharmaceuticals worth $19,498,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. State Street Corp lifted its holdings in Supernus Pharmaceuticals by 1.4% in the fourth quarter. State Street Corp now owns 2,219,228 shares of the specialty pharmaceutical company’s stock valued at $110,296,000 after acquiring an additional 31,668 shares during the period. Geode Capital Management LLC lifted its stake in shares of Supernus Pharmaceuticals by 4.5% in the 4th quarter. Geode Capital Management LLC now owns 1,472,899 shares of the specialty pharmaceutical company’s stock valued at $73,215,000 after purchasing an additional 62,875 shares during the period. Loomis Sayles & Co. L P lifted its stake in shares of Supernus Pharmaceuticals by 12.7% in the 4th quarter. Loomis Sayles & Co. L P now owns 1,448,842 shares of the specialty pharmaceutical company’s stock valued at $72,007,000 after purchasing an additional 162,905 shares during the period. Stephens Investment Management Group LLC boosted its holdings in Supernus Pharmaceuticals by 4.5% during the fourth quarter. Stephens Investment Management Group LLC now owns 1,406,522 shares of the specialty pharmaceutical company’s stock worth $69,904,000 after buying an additional 61,120 shares in the last quarter. Finally, Woodline Partners LP boosted its holdings in Supernus Pharmaceuticals by 63.5% during the third quarter. Woodline Partners LP now owns 1,263,811 shares of the specialty pharmaceutical company’s stock worth $60,398,000 after buying an additional 490,835 shares in the last quarter.

Supernus Pharmaceuticals Stock Performance

NASDAQ:SUPN opened at $44.75 on Friday. The stock has a market capitalization of $2.60 billion, a PE ratio of -87.75, a P/E/G ratio of 0.96 and a beta of 0.55. Supernus Pharmaceuticals, Inc. has a fifty-two week low of $30.93 and a fifty-two week high of $59.68. The company has a fifty day moving average of $47.53 and a two-hundred day moving average of $49.49.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on SUPN shares. Wall Street Zen cut shares of Supernus Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Saturday, May 23rd. Zacks Research raised shares of Supernus Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Monday, April 27th. Finally, Weiss Ratings restated a “sell (d+)” rating on shares of Supernus Pharmaceuticals in a research report on Friday, March 27th. Four research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $62.17.

Supernus Pharmaceuticals Profile

Supernus Pharmaceuticals, Inc, headquartered in Rockville, Maryland, is a specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies. Since its founding in 2003, Supernus has focused on advancing treatments for neurological disorders, with an emphasis on improving patient quality of life through innovative dosage forms and sustained‐release formulations.

The company’s marketed portfolio includes Trokendi XR and Oxtellar XR, extended‐release antiepileptic medications designed to maintain stable drug levels for seizure control, as well as Qelbree (viloxazine extended‐release capsules), approved for the treatment of attention‐deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.